Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia

References

• Wierda WG, Byrd JC, Abramson JS, et al. NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic leukemia, version 4.2020. J Natl Compr Canc Netw. 2020;18(2):185–217.
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176.
   PubMed Web of Science ®Google Scholar
• Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94(3):193–205.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science. 1993;261(5119):358–361.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Ibrutinib [package insert]. Sunnyvale (CA): Pharmacyclics, Inc.; 2015.
   Google Scholar
• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–1678.
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615.
   PubMed Web of Science ®Google Scholar
• Williams AM, Baran AM, Casulo C, et al. Ibrutinib dose adherence and therapeutic efficacy in non-Hodgkin lymphoma: a single-center experience. Clin Lymphoma Myeloma Leuk. 2019;19(1):41–47.
   PubMed Web of Science ®Google Scholar
• Gruber M, Bozic I, Leshchiner I, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019;570(7762):474–479.
   PubMed Web of Science ®Google Scholar
• Garner LM, Kline T, Miller J, et al. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. J Adv Pract Oncol. 2021;12(1):20–28.
   PubMedGoogle Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Sattler ELP, Lee JS, PerriMatthew I, et al. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383–399.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the national cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute; 2017.
   Google Scholar
• Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–376.
   PubMed Web of Science ®Google Scholar
• Dashputre AA, Gatwood KS, Gatwood J. Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia/small lymphocytic lymphoma. J Manag Care Spec Pharm. 2020;26(2):186–196.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and outcomes of ibrutinib-treated patients in the United States: large retrospective analysis of 621 real world patients. Blood. 2016; 128(22):3222.
   Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
   PubMed Web of Science ®Google Scholar
• McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34(5):481–494.
   PubMed Web of Science ®Google Scholar
• St. Charles M, Bollu VK, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood. 2009;114(22):2209–2209.
   PubMed Web of Science ®Google Scholar
• Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379–386.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307.
   PubMed Web of Science ®Google Scholar
• Akhtar OS, Attwood K, Lund I, et al. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019;60(7):1650–1655.
   PubMed Web of Science ®Google Scholar
• Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019;14(3):197–205.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364–2373.
   PubMed Web of Science ®Google Scholar
• Muluneh B, Schneider M, Faso A, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14(6):e324–e334.
   PubMed Web of Science ®Google Scholar
• Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology/Oncology Pharmacist Association best practices for the management of oral oncolytic therapy: pharmacy practice standard. J Oncol Pract. 2019;15(4):e346–e355.
   PubMed Web of Science ®Google Scholar
• Colombo LRP, Aguiar PM, Lima TM, et al. The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J Clin Pharm Ther. 2017;42(4):414–424.
   PubMed Web of Science ®Google Scholar
• Gordon MJ, Kaempf A, Sitlinger A, et al. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021;27(17):4814–4824.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar